Creating a new nasal vaccine to prevent respiratory syncytial virus (RSV) infections.
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein
This study is working on a new nasal spray vaccine for respiratory syncytial virus (RSV) to help protect babies and older adults from serious respiratory illnesses caused by this common virus.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bluewillow Biologics, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10754503 on NIH RePORTER |
What this research studies
This research focuses on developing an innovative intranasal vaccine for respiratory syncytial virus (RSV), which is a common virus that can cause severe respiratory illnesses. The approach involves using a recombinant protein from the virus combined with a special delivery system called a nanoemulsion to enhance the immune response. By targeting both systemic and mucosal immunity, the vaccine aims to provide better protection against RSV, especially in vulnerable populations such as infants and the elderly. The research will manufacture clinical materials necessary for future testing of this vaccine.
Who could benefit from this research
Good fit: Ideal candidates for this research include infants, children, and elderly individuals who are at high risk for RSV infections.
Not a fit: Patients who are not at risk for RSV infections or those who have already been vaccinated against RSV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to an effective vaccine that prevents RSV infections, reducing the incidence of related respiratory illnesses.
How similar studies have performed: Other research has shown promise in developing vaccines for RSV, but this specific approach using a nanoemulsion adjuvant is relatively novel.
Where this research is happening
Ann Arbor, United States
- Bluewillow Biologics, INC. — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Trabbic, Kevin — Bluewillow Biologics, INC.
- Study coordinator: Trabbic, Kevin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.